1332 — Touyun Biotech Cashflow Statement
0.000.00%
Last trade - 00:00- HK$799.59m
- HK$1.25bn
- HK$159.97m
Annual cashflow statement for Touyun Biotech, fiscal year end - December 31st, HKD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | C2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | HKAS | HKAS | HKAS | HKAS | HKAS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -172 | -123 | -199 | -273 | -88.4 |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | 127 | 104 | 179 | 212 | 45.3 |
| Unusual Items | |||||
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.804 | -57.2 | -39.6 | 26.2 | -36.3 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -15.3 | -53.8 | -26.4 | 2.18 | -49.9 |
| Capital Expenditures | -126 | -251 | -12.9 | -17.1 | -3.66 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | 77.6 | 103 | -4.32 | -53.8 | -0.992 |
| Sale of Business | |||||
| Sale of Fixed Assets | |||||
| Change in Net Investments | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -47.9 | -148 | -17.2 | -70.9 | -4.66 |
| Financing Cash Flow Items | 232 | 29 | 20.9 | 12.5 | 30.9 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 160 | 123 | 103 | -26.2 | 35.7 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 102 | -82.2 | 67.9 | -93.6 | -18.2 |